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ABSTRACT  
Objective: The objective of the presented study was to analyze the haematological parameters in female breast cancer (BC) patients before the start 
of the treatment.  
Methods: The study was conducted among female BC patients, visited King Fahd Hospital (KFH), Al Ahsa, Kingdom of Saudi Arabia (KSA) from 
January 2013 to December 2016. A retrospective analytical study was conducted. We analyzed the relationship of haematological parameters with 
various stages of breast cancer before the start of any treatment. We used complete blood count (CBC) reports to analyze the haematological 
parameters. The mean age of the patients was 57 y (31-83 y). Most of the patients were postmenopausal (51-59 y old). We divided the patients into 
4 groups according to the disease stage, i.e., stage 1 (S1) to stage 4 (S4).  
Results: Among altered blood parameters, decreased haemoglobin (Hb 4.5-11 g/dl) and increased erythrocyte sedimentation rate (ESR 37–49 
mm/first hour) in S1 to S4, increased neutrophil count in S3 and S4 (8.3-9.6 x103/mm3), and increased lymphocyte count (4-7.2 x103/mm3) in S1 
and S2 patients were found.  
Conclusion: We found significant variations in haematological parameters at different stages of breast cancer. CBC is indeed an efficient and cost-
effective investigation. By managing these parameters, treatment efficacy and survival rate of BC patients may be augmented.  
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Breast cancer (BC) has frequently displayed a high influence towards 
the health of females globally including the Kingdom of Saudi Arabia 
(KSA). Every year, more than 1.4 million new cases of BC are 
diagnosed. It has been described to be the most common cancer and 
the leading cause of cancer mortality in females. Cancer itself conveys 
remarkable emotional, social, economic, and public health 
consequences [1]. The incidence rates of BC in females of the Arab 
world have increased in the last 24 y; with an increase in the number 
of females being diagnosed with advanced stages of this cancer [2]. It 
has been reported that through the early detection of BC by means of 
screening activities, the morbidity and mortality rates have been 
successfully reduced [3, 4]. Regardless of these results, Arab females 
showed low participation in BC screening activities [5]. An elaborated 
data has been reported on BC in Western countries and developed 
nations, but in the KSA it seems either scattered or not brought to 
attention [6]. Clinically, early BC patients usually do not present with 
the complaint of pain. When the malignancy grows, it causes 
alterations in the shape or size of the breast. In many cases, a mass 
may be noticed by the patient in the affected breast. In progressive 
cases, the malignancy may display the signs of fixation to the chest 
wall and the ulcerations of the skin. Large lymph nodes may be 
present in severe cases [7, 8]. If one of these symptoms appears a 
suitable investigation such as, ultrasonography or tissue biopsy should 
be implemented to diagnose the disease at early stages [9-11]. In 
addition to these investigations, complete blood count (CBC) has its 
own significance. It provides information on haematological 
parameters such as morphologies and counts of red blood cells 
(RBCs), white blood cells (WBCs), platelets, and the erythrocyte 
sedimentation rate (ESR). It is indeed an essential and cost-effective 
investigation demanded from all patients with malignancy before the 
use of chemotherapy, radiotherapy and surgery. Many studies have 
shown the adverse outcome of malignancies in the patients who have 
poor haematological parameters. The Hb [12, 13], ESR level [14], and 
the white blood cell (WBC) counts, including full and differential [15-
17], predict the severity and mortality risk of cancer patients. Platelet 
count aids to monitor the progress of cancer. Cancer cells secret pro-
coagulants and inflammatory cytokines which trigger the activation of 
the coagulation system and consumption of platelets, resulting in 
multiple organ failure and death [18]. Thus, CBC helps a health care 
professional to further investigate any underlying pathology and treat 
accordingly. Every kind of disease that varies in terms of disease 
progression has, in fact, a direct influence towards haematological 
parameters. Breast cancer likewise has its effects on these parameters 
[19]. Hence, it is essential to study the haematological parameters in 
BC patients before, during and after the onset of treatment. In the 
current study, we analyzed the haematological parameters of BC 
patients before the start of the treatment. 
MATERIALS AND METHODS 
The study was conducted among female BC patients, visited King Fahd 
Hospital (KFH), Al Ahsa from January 2013 to December 2016. We 
obtained the approval from the institutional review board of KFH, Al 
Ahsa, KSA (Notary verified letter reference no: 2270204). We conducted 
a retrospective study on haematological parameters by interpreting the 
results of CBC and ESR and analyzed their associations with various 
stages of breast cancer before the start of chemotherapy, radiotherapy, 
or surgery. The medical records and haematological parameters of 100 
female BC patients were retrieved and analyzed. The mean age of the 
patients was 57 y (31-83 y). Most of the patients (92) were 
postmenopausal (51-59 y old). We divided the patients into four groups 
according to the disease stage, i.e., stage 1 (S1), stage 2 (S2), stage 3 (S3) 
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and stage 4 (S4). The haematological parameters included haemoglobin 
(Hb), mean corpuscular volume (MCV), erythrocyte sedimentation rate 
(ESR), platelet count (PC), total leucocyte count (TLC), and differential 
leucocyte count (DLC) i.e., absolute counts of neutrophils, lymphocytes, 
monocytes, eosinophils and basophils.  
Statistical analysis 
The data were analyzed using SPSS version 16. The patients were 
presented as the number and the percentage in each stage of the 
disease. The haematological parameters were presented as 
mean±standard deviation (SD).  
RESULTS 
Among total 100 patients, 40 were in S1, 36 in S2, 18 in S3 and 6 in S4. 
The staging was done by the consultant oncologists and pathologists of 
the hospital as per the standard guidelines, described [20]. Among these 
patients, anaemia (low Hb level) was found in the following number and 
percentage of patients in each individual group. 9 patients (22.5%) in S1, 
5 patients (13.88%) in S2, 5 patients (27.77%) in S3 and 3 patients 
(50%) in S4. The anaemia was mild (Hb 8-11 g/dl) in S1, S2 and S3 
patients, while moderate to severe (Hb 4.5-7.5 g/dl) in S4 patients 
(normal Hb 12-16 g/dl). Fig. 1 shows the level of haemoglobin and the 
percentage of anaemic patients in each disease stage. Morphologically, 
the RBCs were normocytic normochromic with the MCV 81-96 fl 
(normal 80-100 fl). The ESR remained moderately raised (37-49 
mm/first hour) (normal<20 mm/first hour) in almost all (98) patients 
(fig. 2). The total leukocyte count (TLC) remained under normal range 
(4-11 x103/mm3) in all patients; but, absolute neutrophil count was 
found to be raised (8.3-9.6 x103/mm3) (normal 2.5-7.5 x103/mm3) in 5 
patients (27.77%) of S3 and 2 patients (33.33%) of S4 (fig. 3). These two 
neutrophilic patients from S4 had concomitant severe anaemia. Absolute 
lymphocyte count was found to be raised (4-7.2 x103/mm3) (normal 1.5-
3.5 x103/mm3) in 16 patients (40%) of S1 and 5 patients (13.88%) of S2 
(fig. 4). All these results are summed up in table 1. Other differential 
(monocyte, eosinophil and basophil) and platelet counts were within 
normal range. The normal laboratory values of the haematological 
parameters have been described [21].
 
 
Fig. 1: Anaemic patients with Hb level.  % of patients in individual stage.  Hb (g/dl). Hb is presented as mean±standard deviation (SD). 
Normal Hb level: 12-16 g/dl. Total number of patients (n=100) 
 
 
Fig. 2: Patients with raised ESR.  % of patients in individual stage.  ESR (mm/fisrt h). ESR is presented as mean±standard deviation 
(SD). Normal ESR level: <20 mm/first h, total number of patients (n=100) 
 
 
Fig. 3: Patients with Neutrophilia.  % of patients in individual stage.  Neutrophil count (x103/mm3). Neutrophil count is presented as 
mean±standard deviation (SD). Normal neutrophil count: 2.5-7.5 x103/mm3. Total number of patients (n=100) 
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Fig. 4: Patients with lymphocytosis.  % of patients in individual stage.  Lymphocyte count (x103/mm3). Lymphocyte count is presented 
as mean±standard deviation (SD), Normal lymphocyte count: 1.5-3.5 x103/mm3. Total number of patients (n=100) 
 
Table 1: Haematological parameters of breast cancer patients 
Breast cancer stage Normal  Stage 1 Stage 2 Stage 3 Stage 4 
Hb (g/dl) (mean±SD)  14±2 9.5±1.5 9.5±1.5 9.5±1.5 6±1.5 
No. of patients  9 out of 40  5 out of 36  5 out of 18  3 out of 6  
% of patients  22.50% 13.88% 27.77% 50% 
ESR(mm/first h) (mean±SD)  10±10 40±4 42±6 43±6 43±6 
No. of patients   39 out of 40  36 out of 36  17 out of 18 6 out of 6  
% of patients  97.50% 100% 94.40% 100% 
Neutrophil count (x103/mm3) (mean±SD) 5±2.5 5±2.5 5±2.5 8.95±0.65 8.95±0.65 
No. of patients   40 out of 40 36 out of 36  5 out of 18  2 out of 6  
% of patients  100% 100% 27.77% 33.33% 
Lymphocyte count (x103/mm3) (mean±SD) 2.5±1 5.7±1.5 5.5±1.5 2.5±1 2.5±1 
No. of patients    16 out of 40 5 out of 36  18 out of 18  6 out of 6  
% of patients   40% 13.88% 100% 100% 
Total number of patients (n=100). The above parameters are expressed in: Hb (g/dl), ESR (mm/first hr), Neutrophil count (x103/mm3), Lymphocyte 
count (x103/mm3).  
 
DISCUSSION 
Complete blood count (CBC) is a basic and an essential investigation 
for any disease prior to the treatment. Through this investigation, 
various haematological parameters are measured. Alterations in any 
of those may further help investigate the underlying potential causes 
and treat them accordingly. Hence, it helps to improve the general 
health, immunity and tolerance of the patient to the treatment. 
Likewise, it is an important investigation for breast cancer (BC) 
patients prior to the start of any treatment, i.e., chemotherapy, 
radiotherapy or surgery. In the current study, we analyzed the 
haematological parameters of the female BC patients. We found 
significant variations in their haematological parameters. Around ¼ 
(22%) of the total BC patients were found to have decreased Hb 
levels. The patients showed normocytic normochromic anaemia. Our 
results significantly correlate with a previous study conducted in 
India, which showed decreased Hb level in more than 60% of breast 
cancer patients. Those patients also displayed normocytic 
normochromic anaemia [22]. As India is a heavily populated country 
with poor socio-economic conditions, decreased Hb level in the 
majority of these patients could be due to nutritional deficiencies 
[23]. Contrary to that, KSA people have a good nutritional and a 
higher socio-economic condition, hence less number of patients 
were anaemic, which may have resulted from various factors, such 
as, cytokine secretion by tumor cells, or decreased production of 
erythropoietin. Based on previous reports, it was shown that chronic 
diseases and cancers could cause decreased levels of erythropoietin, 
leading to decreased production of RBCs with resulting anaemia 
[24]. The other possible cause of anaemia in our patients might be 
the metastasis of cancer cells to bone marrow, which seems less 
likely as it would have also caused the suppression of other 
haematological series. In addition to this, stage 1 patients also were 
anaemic in which there is no metastasis. Nevertheless, the 
metastasis in the initial stages cannot be completely ruled out. 
Haematopoiesis suppression due to metastasis of breast cancer cells 
to bone marrow has already been described [25, 26]. On the other 
hand, low Hb level has been shown to cause poorer oxygenation of 
tumor cells, which could activate the metastatic genes, leading to the 
metastasis and resistance of cancer cells to chemo and radiotherapy, 
resulting in the worse survival of BC patients [12-13]. Hence, Hb is an 
important parameter, which may be improved in these patients, for 
example through the exogenous administration of erythropoietin [27]. 
Furthermore, we found a significant raise in ESR in almost all BC 
patients. Increased ESR has been found in many malignant diseases 
including breast cancer and several inflammatory disorders [28], and 
has been frequently associated with a much poorer prognosis [14, 28].  
Total leucocyte count (TLC) on the other hand was normal in our 
patients, but the absolute neutrophil count was found to be raised in 
S3 and S4 patients. Previously, Rana AP and his team of medical 
experts reported increased neutrophil count in advanced stages of 
BC patients [22]. The increase in neutrophil count may indicate 
various conditions, such as bacterial infection [29], or increased 
cytokine release by cancer cells, which helps them disseminate to 
other sites [30, 31]. Previous reports have shown that increased 
neutrophil count is often associated with poor prognosis of breast 
and other cancers [15, 16].  
Absolute lymphocyte count was found to be slightly raised in our S1 
and S2 BC patients. Our results correlate with two other studies 
which showed increased lymphocyte count in the early stage of BC 
patients [22, 31]. Increased lymphocyte count may be indicative of a 
good prognosis as it was reported to favor the survival of BC 
patients [32, 33]. Increased lymphocyte count has also been 
reported in other cancers such as gastric and head and neck 
carcinomas [34]. Lymphocytes, specifically CD8+cells and natural 
killer (NK) cells, are known to play an anti-tumorigenic role in many 
cancers. NK cells kill the tumor cells without any prior sensitization. 
Lee and his group reported that even the BC patients with advanced 
stage who had higher lymphocyte count had a better prognosis than 
Ashok et al. 
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the patients with lower lymphocyte count [17]. Nonetheless, many 
breast cancer cells down-regulate the expression of their surface 
antigens, specifically class 1 major histocompatibility complex 
(MHC-I), thus evading the recognition by immune cells [17, 35]. In 
such situations, the lymphocyte count may remain under normal 
range. In contrast, it has also been shown that if MHC antigens are 
down regulated to avoid T cell recognition, they become susceptible 
to be invaded by NK cells, another type of lymphocytes [36]. Thus, 
depending upon the cancer cell antigen expressions and immune 
response, the lymphocyte count may be elevated, or may remain 
within normal range. Hence, absolute counts of WBCs also provide 
with the significant information towards managing the disease.  
CONCLUSION 
We found significant variations in haematological parameters, which 
differed considerably at various stages of our breast cancer patients. 
Decreased Hb and increased ESR at S1 to S4, increased neutrophil 
count at S3 and S4, and increased lymphocyte count at S1 and S2 were 
found. Hence, these parameters have their own significance which 
provides with the essential information from very basic to advanced 
disease processes. By managing these parameters, patients’ treatment 
response and survival rate may be significantly augmented.  
Study limitation 
In our study, the number of patients was limited to 100, which was 
further divided into four groups according to the disease stage. 
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